文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

新型三氮杂苊烯gepotidacin(GSK2140944)对耐多药淋病奈瑟菌的体外活性

In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

研究检测了新型三氮杂苊烯gepotidacin对252株淋病奈瑟菌临床分离株和国际参考株的体外活性,并与当前或既往推荐抗淋病药物比较。Gepotidacin对所有菌株MIC≤4 mg/L,MIC50为0.5 mg/L,MIC90为1 mg/L,未发现与其他抗菌药物显著交叉耐药,但ParC D86N突变与gepotidacin MIC升高相关。

要点

  • Gepotidacin对252株淋球菌均有体外活性,MIC≤4 mg/L。
  • MtrCDE外排泵失活可降低多数菌株gepotidacin MIC。
  • ParC D86N突变与gepotidacin MIC升高相关。

核心结论

  • Gepotidacin对淋球菌株显示高体外活性,可能成为淋病治疗的有效选择,尤其用于双药抗菌方案及对超广谱头孢菌素耐药或过敏的患者。
  • 作者认为需详细阐明体外和体内耐药产生及机制,并进一步开展淋病临床研究,理想情况下还应包括衣原体和生殖支原体。

研究设计与样本

  • 研究检测gepotidacin对252株淋病奈瑟菌临床分离株和国际参考株的体外活性,并与当前或既往推荐抗淋病药物比较。
  • 采用琼脂稀释法测定gepotidacin的MIC(mg/L),采用Etest法测定其他七种抗菌药物的MIC。
  • 对gyrA和parC基因进行测序,并检查MtrCDE、MacAB和NorM外排泵失活对gepotidacin MIC的影响。

主要发现

  • Gepotidacin对所有淋球菌分离株(n=252)显示强体外活性,MIC≤4 mg/L。
  • Gepotidacin的模态MIC为0.5 mg/L,MIC50为0.5 mg/L,MIC90为1 mg/L,MIC范围为0.032-4 mg/L。
  • MtrCDE外排泵失活(而非MacAB或NorM)可降低多数菌株的gepotidacin MIC。
  • 未发现gepotidacin与任何其他抗菌药物(包括氟喹诺酮类环丙沙星)之间存在显著交叉耐药。
  • 与氟喹诺酮耐药相关的ParC D86N突变(可能伴随其他抗菌药物耐药突变)与gepotidacin MIC升高相关。

局限性

  • 作者认为需详细阐明体外和体内耐药产生及机制,并进一步开展淋病临床研究,理想情况下还应包括衣原体和生殖支原体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Increased antimicrobial resistance surveillance and new effective antimicrobials are crucial to maintain treatable gonorrhoea. We examined the in vitro activity of gepotidacin, a novel triazaacenaphthylene, and the effect of efflux pump inactivation on clinical Neisseria gonorrhoeae isolates and international reference strains (n = 252) and compared gepotidacin with antimicrobials currently or previously recommended for gonorrhoea treatment. METHODS: MICs (mg/L) were determined by agar dilution (gepotidacin) or by Etest (seven other antimicrobials). The gyrA and parC genes were sequenced and the impact of inactivation of the MtrCDE, MacAB and NorM efflux pumps on gepotidacin MICs was examined. RESULTS: Gepotidacin showed potent in vitro activity against all gonococcal isolates (n = 252; MIC ≤4 mg/L). The modal MIC, MIC50, MIC90 and MIC range of gepotidacin were 0.5, 0.5, 1 and 0.032-4 mg/L, respectively. Inactivation of the MtrCDE efflux pump, but not MacAB or NorM, decreased the gepotidacin MICs for most strains. No significant cross-resistance between gepotidacin and any other antimicrobials, including the fluoroquinolone ciprofloxacin, was identified. However, the ParC D86N mutation (possibly together with additional antimicrobial resistance mutation), which is associated with fluoroquinolone resistance, was associated with increased gepotidacin MICs. CONCLUSIONS: Gepotidacin demonstrated high in vitro activity against gonococcal strains, indicating that gepotidacin could potentially be an effective option for gonorrhoea treatment, particularly in a dual antimicrobial therapy regimen and for patients with resistance or allergy to extended-spectrum cephalosporins. Nevertheless, elucidating in vitro and in vivo resistance emergence and mechanisms in detail, together with further gonorrhoea clinical studies, ideally also including chlamydia and Mycoplasma genitalium are essential.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Jacobsson S, Golparian D, Scangarella-Oman N, et al. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2018. PMID: 29796611. doi:10.1093/jac/dky162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。